Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Tocilizumab

Brand: RoActemra®
NICE TA: 518
Indication: Treating giant cell arteritis (NICE TA518)
Disease category: Musculoskeletal system
Commissioning responsibility: NHS England
PbR excluded: Yes

Background

Tocilizumab, when used with a tapering course of glucocorticoids (and when used alone after glucocorticoids), is recommended as an option for treating giant cell arteritis in adults, only if:
• they have relapsing or refractory disease
• they have not already had tocilizumab
• tocilizumab is stopped after 1 year of uninterrupted treatment at most and
• the company provides it with the discount agreed in the patient access scheme.

Recommendation

LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA518 - Tocilizumab for treating giant cell arteritis

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red